Ono Pharmaceutical Co., Ltd.
4528.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥753,691,005 | ¥1,185,087,354 | ¥4,049,392,672 | ¥4,566,886,716 |
| - Cash | ¥204,567,000 | ¥166,141,000 | ¥96,135,000 | ¥69,112,000 |
| + Debt | ¥146,678,000 | ¥8,862,000 | ¥9,168,000 | ¥8,802,000 |
| Enterprise Value | ¥695,802,005 | ¥1,027,808,354 | ¥3,962,425,672 | ¥4,506,576,716 |
| Revenue | ¥486,871,000 | ¥502,672,000 | ¥447,187,000 | ¥361,361,000 |
| % Growth | -3.1% | 12.4% | 23.8% | – |
| Gross Profit | ¥338,921,000 | ¥375,546,000 | ¥337,125,000 | ¥267,850,000 |
| % Margin | 69.6% | 74.7% | 75.4% | 74.1% |
| EBITDA | ¥91,540,000 | ¥182,103,000 | ¥161,896,000 | ¥122,827,000 |
| % Margin | 18.8% | 36.2% | 36.2% | 34% |
| Net Income | ¥50,047,000 | ¥127,977,000 | ¥112,723,000 | ¥80,519,000 |
| % Margin | 10.3% | 25.5% | 25.2% | 22.3% |
| EPS Diluted | 106.41 | 266.6 | 230.79 | 162.16 |
| % Growth | -60.1% | 15.5% | 42.3% | – |
| Operating Cash Flow | ¥82,459,000 | ¥110,660,000 | ¥159,610,000 | ¥61,829,000 |
| Capital Expenditures | -¥7,990,000 | -¥20,829,000 | -¥14,497,000 | -¥12,277,000 |
| Free Cash Flow | ¥74,469,000 | ¥89,831,000 | ¥145,113,000 | ¥49,552,000 |